We frequently hear that we are at the cusp of realizing the promise of molecular medicine. Nowhere is that promise closer to being realized than in the case of fragile X syndrome (FXS). FXS is now considered the gold standard for neurodevelopmental research because it has been barely 20 years from the identification of the gene responsible for the disorder to a putative molecular mechanism, resulting in multiple drugs undergoing clinical trials for treatment of patients. However, a concern of clinicians and hopeful parents has been ''what if it's too late''? Autism and related disorders such as FXS always have been thought to be irreversibly set within a critical window during early childhood development between birth and 3 years of age. Often times, by the time FXS is diagnosed unambiguously, that window already has passed, which limits intervention options considerably. In the current issue of Neuron, Michalon et al. (2012) offer a bright ray of hope by comprehensively demonstrating the reversal of a wide variety of FXS phenotypes in adult mice with CTEP, a new selective antagonist of mGluR5 (Figure 1) .
One of the most enduring hypotheses in FXS research has been the ''mGluR theory,'' which posits that many abnormalities associated with FXS are caused by excessive metabotropic glutamate receptor 5 (mGluR5) signaling. This excessive signaling results in exaggerated protein synthesis, which triggers an array of abnormal synaptic plasticity and behaviors (Bear et al., 2004) . The theory was derived from basic science studies of hippocampal synaptic plasticity (Huber et al., 2002 ) that showed enhanced metabotropic glutamate receptor-dependent long-term depression (mGluR-LTD) in FXS mice. Major support for the mGluR theory of FXS came soon thereafter from two sets of findings, the first of which was in Drosophila (McBride et al., 2005) and demonstrated that deletion of dfmr1 gene produced synaptic and behavioral deficits that could be counteracted by mGluR antagonists. The second study was the seminal paper of Dö len et al. (2007) that reported a wide variety of molecular, cellular, and behavioral phenotypes in FXS model mice could be corrected with a 50% genetic reduction of mGluR5 expression. This study provided a proof of principle and made mGluR5 a bona fide target for FXS therapy that ramped up the search for high-fidelity blockers of this receptor.
MPEP and fenobam are mGluR5 antagonists that have been available for several years. Although both compounds efficiently block receptor activity, the downside is that they are extremely shortacting, with a half-life of approximately 15 min in the brain. Even before the genetic studies firmly established the viability of the mGluR theory, it was shown that acute administration of MPEP to FXS model mice could reduce hyperactivity in an open field arena and abolish susceptibility to audiogenic seizures (Krueger and Bear, 2011) . However, chronic MPEP administration was not a treatment option for individuals with FXS because its short half-life precluded extended receptor blockade and increased the likelihood of ''yo-yo-ing'' mGluR signaling when the drug was cleared. Nevertheless, valuable information on pharmacological blockade of mGluR system was gleaned through these and several other studies. Daily injections of MPEP and a GluR1 antagonist JNJ16259685 showed that they were effective in alleviating repetitive behaviors and enhanced motor learning in FXS mice (Thomas et al., 2012) . In addition, MPEP has been useful in dissecting the molecular pathways disrupted in FXS, which include dendritic spine abnormalities, expression of LTD through AMPAR trafficking, and neocortical longterm potentiation, to name just a few (Krueger and Bear, 2011) . However, the bigger problem still remained. If one could not study effects of the long-term blockade of mGluR5 signaling, treatments based on mGluR theory would remain a distant dream. That was until, CTEP. Michalon et al. (2012) used CTEP, a recently launched negative allosteric inhibitor of mGluR5 with inverse agonist properties, which unlike previous mGluR5 antagonists, has extremely long receptor occupancy, with a half-life of 18 hr (Lindemann et al., 2011) . A single dose of CTEP administered every 48 hr, achieved uninterrupted mean receptor occupancy of 81%. What makes CTEP even more attractive is that unlike MPEP, it can be provided orally. The authors found that FXS model mice treated with a single dose of CTEP exhibited normal levels of brain protein synthesis, normal expression of mGluR-dependent LTD, and protection against audiogenic seizures. Longer treatment of the FXS mice with CTEP rectified certain cognitive deficits, dendritic abnormalities in the visual cortex and elevated ERK and mTOR signaling in the cortex. Intriguingly, they also observed a partial correction of macro-orchidism, demonstrating for the first time the involvement of mGluRs in this peripheral FXS phenotype. This report is also notable for the inclusion of a section describing how well the mice tolerated the chronic treatment of CTEP for 4 and 17 weeks. The authors found a minimal reduction in body weight gain and a small reduction in grip strength in CTEP-treated mice. The lack of major side effects bolsters the claims that CTEP should be the inhibitor of choice for mGluR5 targeting in FXS. A crucial litmus test that remains for CTEP is to determine whether it improves the social-interaction defects that form a major part of the cognitive problems associated with autism spectrum disorder (ASD). It is well established that 50%-60% of all FXS patients display symptoms of ASD (Hagerman et al., 2011) .
The groundbreaking finding in the study of Michalon et al. (2012) was the reversal of phenotypes in FXS mice at an age when brain maturation is mostly complete. Developmental disorders by their very nature alter the course of proper neuronal and brain growth via alterations in either signaling or cellular processes that interfere with timely plasticity and circuit construction. The silencing of genes such as FMR1 starts impacting patients from very early stages of development. Thus, the debate has been whether the aberrant plasticity and circuits that have been established quite early in postnatal life with little room for modification or whether there is residual plasticity in these circuits that can then be tweaked with pharmacological interventions. Because most diagnoses for developmental disorders are done after substantial and undeniable cognitive deficits are observed (1-3 years of age), this issue has had grave implications for any pharmacologicalbased therapies. Previous studies of FXS and Rett syndrome model mice demonstrated that postdevelopmental interventions could correct an array of abnormalities that would have been predicted due to aberrant brain development, but these studies were based on genetic approaches (Hayashi et al., 2007; Guy et al., 2007) . The big question remained whether a pharmacological regimen also could correct diverse brain abnormalities in a mouse model of FXS. A previous study showed that 2 weeks of MPEP treatment rescued aberrant dendritic morphology in FXS mice, but only when treatment started at birth and not in older mice (Su et al., 2011) . In contrast, CTEP shows promise in not only reversing dysregulated mGluR5 signaling, but also in reversing circuit-level disruptions, which is reflected in the amelioration of abnormal behaviors displayed by the FXS mice. Thus, neuronal circuitry in FXS, and perhaps related developmental disorders associated with autism, are not ''hardwired'' during development but may differ because of altered signaling that can be corrected even in adulthood. This body of work not only emphatically answers a key concern in the field, but also raises the bar for assessing the efficacy of other candidate molecules (AFQ056 from Novartis, RO4917523 from Roche, and STX209 from Seaside Therapeutics) that are either undergoing or have completed clinical trials, with the FXS community anxiously awaiting results (http://www.clinicaltrials.gov).
According to a recently published screen, FMRP associates with more than 800 mRNA molecules (Darnell et al., 2011) . Only a fraction of the protein products of these mRNAs are involved in mGluR signaling, with the highest number being related to broad-spectrum GTPase signaling. In addition, the role of FMRP in nonneuronal cells, where it is abundant during prenatal development, is not well understood (Hinds et al., 1993) . Therefore, there likely are limits to the applicability of the mGluR theory as the sole, causal basis of FXS. Another enduring phenomenon of FXS has been elevated systemic rates of protein synthesis and deviant signaling that impacts translational control (LiuYesucevitz et al., 2011) . It will be important to comprehensively assess whether CTEP can reset the abnormal translational control observed in FXS.
In closing, although CTEP may not be the panacea for all of the ills of FXS, it is a major step forward toward a viable therapy for FXS. In addition, the studies of Michalon et al. (2012) are an excellent example of the preclinical/translational studies that are bridging the gulf between the foundational work of basic, mechanistic science and viable clinical therapies for brain disorders, thereby realizing the promise of molecular medicine. 0 end of Fmr1 gene, resulting in transcriptional silencing and the subsequent loss of fragile mental retardation protein (FMRP). The lack of FMRP is widely thought to alter synaptic plasticity and circuits critical for pre-and early postnatal stages of brain development, otherwise known as the ''critical developmental window.'' This altered development causes deficits in the cognitive capabilities of individuals afflicted with FXS. Earlier theories supported the notion that effective treatment for developmental disorders such as FXS could only occur during the critical developmental window, after which the brain would be hard wired. In the current issue of Neuron, Michalon et al. (2012) show that administration of CTEP, which blocks mGluR5 signaling after the window, can ameliorate FXS phenotypes.
Axonal target-derived BMP and neurotrophin signaling are both known to regulate neuronal gene expression, differentiation, and axon growth. In this issue of Neuron, Ji and Jaffrey (2012) discovered that BMP-signaling endosomes depend on BDNF-induced axonal synthesis of SMADs to retrogradely regulate transcription in developing trigeminal neurons, providing a mechanism of integrating the two target-derived signals.
During nervous system development, axonal target-derived signals can induce transcriptional changes which are essential for neuronal differentiation and correct assembly of neural circuits. The rodent trigeminal sensory system has served as an excellent model to study such processes. Cutaneous sensory information from three distinct facial regions is transmitted to the brain by the three branches of the trigeminal ganglion: ophthalmic (Op), maxillary (Mx), and mandibular (Md) branches ( Figure 1A) . A number of facial target-derived signals have been shown to regulate different aspects of the specification, peripheral axon growth, central axon projection, and survival of developing trigeminal sensory neurons (Davies, 1997; O'Connor and Tessier-Lavigne, 1999; Hodge et al., 2007; da Silva et al., 2011) . Two factors in particular, brain-derived neurotrophic factor (BDNF) and bone morphogenic protein 4 (BMP4), have been the focus of recent study, including a paper in this issue of Neuron from Ji and Jaffrey (2012). In early embryonic development, between embryonic days E10 and E12, BDNF is expressed by both the ophthalmic and maxillary targets as well as the corresponding pathway mesenchyme, and it serves as one of the ''chemoattractants'' that attract the axon outgrowth of trigeminal peripheral axons ( Figure 1A ; O'Connor and TessierLavigne, 1999) . After initial axon extension, BMP4, which is also selectively expressed by epidermis in the ophthalmic and maxillary regions at these stages, retrogradely signals to trigeminal neurons and induces spatially patterned expressions of several transcription factors along the dorsoventral axis of the trigeminal ganglion (Hodge et al., 2007) . One such BMP4-retrograde signaling induced gene is Tbx3 ( Figure 1A) .
The intracellular mechanisms that mediate this BMP4-retrograde signal in trigeminal neurons have been unclear. Ji and Jaffrey (2012) describe an interesting union between BDNF-induced axonal translation of SMADs (which are effectors carrying out the BMP transcriptional signaling) and axon-derived BMP4-signaling endosomes that together mediate the retrograde specification of trigeminal neurons (summarized in Figure 1B) .
Using microfluidic chambers for compartmentalized cultures and separate manipulations of trigeminal neuron cell bodies versus axons, the authors established that adding BMP4 to the axons resulted in the appearance of phosphorylated-SMAD1/5/8 (pSMADs) within 15 min and Tbx3 gene transcription within 4 hr in the neuronal cell bodies. To show
